Related Experiment Video

Updated: Apr 27, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K

[Research progresses of Mycobacterium tuberculosis cytochrome P450s as a potential drug target]

Yun Lu, Feng Qiao, Xue-Fu You

    Yao Xue Xue Bao = Acta Pharmaceutica Sinica
    |July 1, 2014
    PubMed

    Insights

    Identifying new targets is crucial for antituberculosis (TB) drug discovery. This review explores Mycobacterium tuberculosis (Mtb) CYP450 enzymes as potential anti-TB drug targets, analyzing their features and interactions with inhibitors.

    Area of Science:

    • Biochemistry
    • Microbiology
    • Drug Discovery

    Background:

    • Tuberculosis (TB) remains a significant global health challenge, necessitating novel drug development.
    • Mycobacterium tuberculosis (Mtb) encodes 20 CYP450 enzymes involved in essential cellular processes.
    • Several Mtb CYP450 enzymes are emerging as promising targets for new anti-TB therapies.

    Purpose of the Study:

    • To review and summarize the phylogenetic analysis, structural characteristics, and enzymatic functions of Mtb CYP450s.
    • To analyze the interaction mechanisms between Mtb CYPs and selective inhibitors, including azole antifungals.
    • To assess the druggability of Mtb CYPs for high-throughput screening and rational drug design.

    Main Methods:

    • Phylogenetic analysis of Mtb CYP450 enzymes.
    • Review of structural and functional data for Mtb CYPs.
    • Analysis of inhibitor-CYP interaction mechanisms.
    • Evaluation of CYP druggability for anti-TB drug discovery.

    Main Results:

    • Mtb possesses 20 CYP450 enzymes with diverse roles in lipid metabolism and respiration.
    • Structural data for six Mtb CYPs are available, highlighting their potential as drug targets.
    • Azole antifungal agents demonstrate inhibitory interactions with certain Mtb CYPs.

    Conclusions:

    • Mtb CYP450 enzymes represent a viable class of targets for novel antituberculosis drug development.
    • Understanding Mtb CYP structure-function relationships and inhibitor interactions is key to designing effective drugs.
    • The druggability analysis supports the use of Mtb CYPs in screening and rational design strategies for new TB therapeutics.

    More Related Videos

    A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

    A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

    Published on: March 24, 2017

    7.4K
    A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening15:28

    A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

    Published on: January 17, 2014

    7.3K

    Related Concept Videos

    Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

    Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

    Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
    337
    Pulmonary Tuberculosis V01:28

    Pulmonary Tuberculosis V

    Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
    Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
    984
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    81
    Targets for Drug Action: Overview01:26

    Targets for Drug Action: Overview

    Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
    Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
    9.1K
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    119